Additionally, a clinical study involving 202 cancer patients treated with an OAd identified low baseline serum levels of high mobility group box 1 protein (HMGB1) as an independent positive prognostic and predictive factor for oncolytic immunotherapy in individuals with advanced cancer (203). This evidence concerns the gene HMGB1 and cancer.